Share This Page
Suppliers and packagers for generic pharmaceutical drug: XENON XE-129 HYPERPOLARIZED
✉ Email this page to a colleague
XENON XE-129 HYPERPOLARIZED
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Polarean | XENOVIEW | xenon xe-129 hyperpolarized | GAS;INHALATION | 214375 | NDA | Polarean, Inc. | 80534-0300-1 | 50 BAG in 1 CARTON (80534-0300-1) / 300 mL in 1 BAG | 2022-12-23 |
| Polarean | XENOVIEW | xenon xe-129 hyperpolarized | GAS;INHALATION | 214375 | NDA | Polarean, Inc. | 80534-0500-1 | 50 BAG in 1 CARTON (80534-0500-1) / 500 mL in 1 BAG | 2022-12-23 |
| Polarean | XENOVIEW | xenon xe-129 hyperpolarized | GAS;INHALATION | 214375 | NDA | Polarean, Inc. | 80534-0750-1 | 50 BAG in 1 CARTON (80534-0750-1) / 750 mL in 1 BAG | 2022-12-23 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for XENON XE-129 Hyperpolarized (Xe-129): Who Manufactures, Supplies, and How the Value Chain Works
Xenon Xe-129 hyperpolarized (“hyperpolarized xenon”) is supplied through a tight manufacturing value chain that typically combines (1) bulk xenon supply, (2) proprietary polarizing hardware and process know-how, and (3) regulated, dose-ready clinical radiopharmacy distribution for MRI use. Current commercial availability is concentrated in a small set of specialized suppliers tied to specific production platforms and clinical partner networks.
The core supply constraint is not bulk xenon gas price alone. The limiting factors are the hyperpolarization process (equipment + process IP), unit-dose production throughput, helium/xenon handling infrastructure, sterile/inert transfer logistics, and compatibility with clinical site workflows for inhaled administration.
Who supplies hyperpolarized Xe-129 for MRI right now?
Answer: Supply is dominated by specialized hyperpolarization-platform vendors and contract production models tied to clinical imaging deployments. Bulk xenon is generally sourced from industrial gas suppliers, but hyperpolarized Xe-129 as an administered clinical product is produced only by parties with working polarizer systems, validated production procedures, and established distribution channels.
What counts as a “supplier” for Xe-129 hyperpolarized?
Three different supplier categories drive availability:
- Industrial gas suppliers (upstream xenon)
- Provide xenon gas (Xe) feedstock, sometimes with specified isotopic composition or QA documentation.
- Hyperpolarization system suppliers and system operators
- Provide or operate the polarizer (laser/electronics/magnetics architecture, cryogenic handling, gas processing, and control software).
- Clinical dose product manufacturers / radiopharmacy distributors
- Produce dose-ready, site-dispatched hyperpolarized xenon and support clinical training, site setup, and quality documentation.
In most real-world deployments, categories 2 and 3 are effectively bundled because hyperpolarized Xe-129 is hard to decouple from the polarizer platform.
Supplier landscape by function
| Supply function | Typical supplier type | Key constraints |
|---|---|---|
| Bulk Xe feedstock | Industrial gas companies | Isotopic specification, traceability, delivery reliability |
| Hyperpolarization hardware | Specialized tech vendors | Proprietary polarizer process, performance qualification |
| Clinical dose supply | Specialized contract manufacturers / polarizer operators | Batch throughput, in-date release testing, site logistics |
| Site delivery support | Clinical service partners | Installation, staff training, MRI workflow integration |
Which companies provide hyperpolarized xenon systems and dose production?
Answer: The hyperpolarized xenon market is historically concentrated around a small number of polarizer platform operators and their clinical supply partners. In practice, many imaging centers receive hyperpolarized xenon through vendor-operated polarizers or through a narrow set of contract production arrangements rather than through general industrial-gas channels.
Polarizer platforms and operational capacity
Suppliers typically compete on:
- polarizer uptime and reliability
- achievable polarization level and reproducibility
- cycle time per unit dose
- distribution method for time-sensitive administration
- post-processing gas handling to match MRI inhalation requirements
Where the “XENON XE-129 HYPERPOLARIZED” label fits
“XENON XE-129 HYPERPOLARIZED” is a drug-like product description for a hyperpolarized xenon formulation used for imaging. Supplier identity depends on whether you mean:
- the polarizer platform (equipment supplier/operator), or
- the clinical dose (dose manufacturer/distributor).
Without additional labeling context (brand, NDA/BLA/clinical program name, or specific FDA listing), supplier attribution at the product level cannot be stated in a single definitive list. However, the market structure is consistent: industrial gases supply xenon feedstock; hyperpolarization operators provide dose-ready material under validated protocols.
What is the typical supply chain for hyperpolarized Xe-129?
Answer: Bulk xenon is delivered to a hyperpolarization production site, then converted into polarized xenon using a proprietary polarizer workflow, then packaged and dispatched to clinical sites quickly enough to maintain usability for inhalation MRI.
Step-by-step value chain
- Bulk xenon procurement
- Industrial suppliers ship Xe to a production facility with QA and traceability controls.
- Hyperpolarization production
- A polarizer platform performs the hyperpolarization process, then prepares the final gas mixture/dose for clinical administration.
- Quality release and documentation
- Batch records, gas handling logs, and release documentation are generated per the applicable regulatory framework (often under clinical supply arrangements).
- Time-sensitive packaging and dispatch
- Product is transferred and transported to the imaging site with controlled handling to maintain functional performance.
- Site administration and workflow
- Clinical teams administer the inhaled xenon during MRI sequences under the site’s validated protocol.
Why time is a procurement risk
Hyperpolarized gases are constrained by polarization decay over time. That drives:
- production scheduling
- transport logistics
- batch-to-site dispatch windows
- limited buffer inventory
Procurement contracts therefore often price for throughput and scheduling reliability, not just unit materials.
How many supplier options exist, and what are the procurement bottlenecks?
Answer: Supplier options for dose-ready hyperpolarized Xe-129 are limited by polarizer capacity and platform availability. The bottlenecks are usually:
- polarizer system availability (queueing capacity)
- production throughput and QA release turnaround
- clinical site readiness and compatibility
- distribution lead times that fit polarization decay constraints
Bottlenecks that affect contract terms
| Bottleneck | Procurement impact |
|---|---|
| Polarizer queue | Longer lead times, allocation-based contracts |
| Throughput limits | Minimum order quantities tied to scheduling |
| Time-sensitive dispatch | Strict shipping windows, premium logistics |
| Platform compatibility | Some sites can only run certain operational setups |
| Quality documentation | Release documentation requirements can delay approvals |
What regulatory or listing status affects who can supply?
Answer: In the US, hyperpolarized xenon products used in clinical settings typically fall under specific investigational or approved program pathways. Supplier eligibility at the commercial dose level depends on the relevant regulatory pathway and ability to release product under that framework.
FDA pathway mechanics that influence sourcing
Supplier eligibility and contracts are often gated by:
- whether material is supplied as part of an NDA/BLA commercialization or clinical trial
- whether product is distributed through radiopharmacy channels with controlled documentation
- whether the supplier can meet quality system expectations for batch release
Because “XENON XE-129 HYPERPOLARIZED” may be sold for different program contexts (clinical trial vs commercial imaging product), supplier identification must align with the specific regulatory status of the product instance.
How do contracts for hyperpolarized Xe-129 usually price and structure supply?
Answer: Pricing is commonly structured around supply reliability and polarizer capacity, with separate considerations for:
- dose unit economics (gas and operational inputs)
- system utilization and technical support
- distribution logistics and scheduling constraints
- service-level commitments for dispatch windows
Typical contract structure
- capacity reservations (queueing and allocation)
- per-dose or per-session pricing
- service fees for equipment support and site integration
- penalties or terms tied to dispatch and release timing
Industrial gas pricing tends to be a minority component of total cost versus the polarizer and clinical supply operations.
Does hyperpolarized Xe-129 have generic or biosimilar-style substitutes?
Answer: No direct “generic Xe-129 hyperpolarized” substitute is analogous to small-molecule generics or biosimilars in most contexts. The reason is that the product is tightly linked to specialized process equipment, performance, and time-sensitive functional behavior.
What can vary is:
- the polarizer platform and operator
- the production site and dispatch logistics
- the clinical protocol and dosing regimen
Those differences can materially affect performance even if the active species is the same (Xe-129).
Key Takeaways
- Hyperpolarized Xe-129 supply is constrained by polarizer platform capacity and time-sensitive dose logistics more than by bulk xenon availability.
- “Suppliers” generally split into upstream industrial gas sources for xenon feedstock and specialized polarizer operators or dose manufacturers for clinical MRI administration.
- Procurement risk concentrates in scheduling, dispatch windows, and validated operational readiness at clinical sites.
- A definitive, single-product supplier roster for “XENON XE-129 HYPERPOLARIZED” cannot be reliably enumerated without the specific program label or regulatory listing, because supplier identity changes between platform operators and dose distributors.
FAQs
1) Can industrial gas companies supply hyperpolarized Xe-129 directly to hospitals?
Usually not for clinical dose-ready hyperpolarized Xe-129, because industrial gas distributors typically do not operate validated hyperpolarization systems and time-sensitive dose release workflows.
2) What is the main driver of lead time for hyperpolarized Xe-129?
Polarizer scheduling and production throughput, plus dispatch timing relative to polarization decay.
3) What procurement documents matter most for hyperpolarized Xe-129?
Batch records, release documentation, handling logs, and transport dispatch records aligned to the applicable regulatory and clinical protocol.
4) Are there multiple competing suppliers at the dose level?
Competition exists, but options are limited by polarizer platform availability and the narrow set of operators with established clinical supply capability.
5) What drives cost differences among suppliers?
Operational performance (throughput and polarization reproducibility), dispatch logistics, QA release speed, and technical support for site workflow integration.
References
- APA (American Psychological Association) style placeholder.
More… ↓
